GC Biopharma will present expanded aggregation testing across 18 lots of five IVIG products and a new review of ALYGLO Phase 3 safety data. The analyses identify measurable molecular differences and provide additional safety context, but neither establishes comparative clinical superiority.
Lunit will integrate its SCOPE artificial intelligence pathology platform into Discovery Life Sciences' tissue analysis services, expanding access to standardized biomarker research. The collaboration strengthens Lunit's precision oncology strategy, although financial terms, client adoption and new clinical validation outcomes remain undisclosed.
Galderma expands Alastin across Japan and Asia Pacific, linking premium skincare with rising demand for aesthetic procedures.
South Korea keeps Neuronata-R available after Phase 3 review, but manufacturing, patient selection and a delayed U.S. filing remain decisive tests ahead.
FDA Fast Track status advances Arialys Therapeutics’ ART5803 as Phase 2 trials test a precision approach to anti-NMDA receptor encephalitis.